# Actinobac Biomed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actinobac-biomed

- Industry: Biotechnology
- Headquarters: Kendall Park, US
- Website: www.actinobac.com
- Total disclosed funding: $5M
- Latest round: Series A (Jul 3, 2017)
- Investors on record: 2

## About

Actinobac Biomed, Inc. is a biotechnology firm focused on developing innovative solutions for the healthcare sector, particularly in the area of cellular therapies and regenerative medicine.Founded in 2009 in Kendall Park, US, Actinobac Biomed, Inc. specializes in cellular therapies that address medical needs. The company has raised a total of USD 4.4 mn, with its latest funding round being a Series A of USD 4.4 mn in July 2017, led by Kairos Ventures. Scott Kachlany is the founder, and Ben Belinka serves as CEO. Actinobac has closed four deals to date, demonstrating a strategic focus on growth and innovation.Actinobac Biomed, Inc. offers technology solutions designed to improve user experience and operational efficiency in healthcare. Its flagship product is a versatile software platform that integrates with third-party applications for enhanced workflow management. This platform addresses challenges such as patient management and treatment optimization, targeting healthcare providers and institutions. The company's solutions are marketed across North America, Europe, and parts of Asia, catering to a diverse range of clients.Revenue is primarily generated through a subscription-based model, enabling clients to access software and services on a flexible basis. This model includes tiered pricing plans tailored to various business sizes and needs, allowing clients to select packages that best fit their operational requirements. The company also engages in B2B transactions, collaborating with resellers and technology integrators to broaden market reach and enhance user service delivery.Actinobac Biomed, Inc. plans to leverage its recent funding to expand product offerings and enter new markets. The company is focusing on launching new features for its software platform aimed at improving patient care in the upcoming year. Additionally, Actinobac intends to explore opportunities in emerging markets in Asia and Europe by 2025, enhancing its global footprint. The financing obtained in July 2017 will support these initiatives, facilitating the development of new technologies and market expansion efforts.

## Funding rounds

- Series A, Jul 3, 2017, $4.4M — Kairos Ventures
- Seed, Feb 23, 2013, $0.1M — Foundation Venture Capital Group
- Seed, Mar 24, 2009, $0.5M — Foundation Venture Capital Group

## Investors

- Foundation Venture Capital Group (https://capitalatlas.ai/funds/foundation-venture-capital-group) — Seed
- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Series A